• Tien M H Ng, Amardeep K Singh, Joseph F Dasta, David Feldman, and Alexandre Mebazaa.
• Department of Pharmacy, University of Southern California, 1985 Zonal Avenue, Los Angeles, CA 90033, USA. tienng@usc.edu
• Crit Care Clin. 2006 Apr 1;22(2):199-219, v.

AbstractAcute heart failure is an evolving syndrome that continues to be defined by ongoing studies and registries. It is associated with significant morbidity and mortality and places a huge economic burden on health care systems. Improved understanding of the underlying pathophysiologic processes has prompted interest into understanding the implications of current and future pharmacologic management strategies beyond hemodynamics. Diuretics, vasodilators, and inotropes remain the mainstays of therapy with several new classes of agents on the horizon. Clinicians should understand the rationale for use and limitations of each therapy to maximize benefit and cost-effectiveness, while minimizing the potential for adverse outcomes.

15 keywords...

hide…